|
2025 Journal Article SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolomeTillett, Bree J., Dwiyanto, Jacky, Secombe, Kate R., George, Thomas, Zhang, Vivian, Anderson, Dovile, Duggan, Emily, Giri, Rabina, Loo, Dorothy, Stoll, Thomas, Morrison, Mark, Begun, Jakob, Hill, Michelle M., Gurzov, Esteban N., Bell, Kirstine J., Saad, Sonia, Barlow, Christopher K., Creek, Darren J., Chong, Chun Wie, Mariño, Eliana and Hamilton-Williams, Emma E. (2025). SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome. Nature Communications, 16 (1) 2893, 1-20. doi: 10.1038/s41467-025-58319-y |
|
2025 Journal Article Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutationsMoniruzzaman, Md, Wong, Kuan Yau, Janjua, Taskeen Iqbal, Martin, Jennifer H., Begun, Jakob and Popat, Amirali (2025). Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations. ACS Pharmacology and Translational Science, 8 (2), 543-556. doi: 10.1021/acsptsci.4c00644 |
|
2025 Journal Article Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studiesRubin, David T., Allegretti, Jessica R, Panés, Julián, Shipitofsky, Nicole, Yarandi, Shadi S, Huang, Kuan-Hsiang Gary, Germinaro, Matthew, Wilson, Rebbecca, Zhang, Hongyan, Johanns, Jewel, Feagan, Brian G, Hisamatsu, Tadakazu, Lichtenstein, Gary R, Bressler, Brian, Peyrin-Biroulet, Laurent, Sands, Bruce E, Dignass, Axel, Abrahamovych, Orest, Abu-Farsakh, Niazy, Afanasieva, Halyna, Akpinar, Hale, Kharrat, Houssam Al, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Araki, Hiroshi, Argollo, Marjorie, Ariel, Federico ... Zureikat, Firas (2025). Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. The Lancet, 405 (10472), 33-49. doi: 10.1016/S0140-6736(24)01927-5 |
|
2025 Journal Article Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case reportHuynh, David, Khaing, Myat Myat, Fernandes, Richard Gareth, Malloy, Reuben, Lin, Lei, Gilmore, Robert, Walker, Nicole, Khoo, Emi and Begun, Jakob (2025). Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis: a case report. Case Reports in Gastroenterology, 19 (1), 1-6. doi: 10.1159/000542711 |
|
2025 Journal Article Epidemiology and Treatment Patterns of Fistulizing Crohn's Disease in a Large, Real-World Australasian CohortMcNamara, Jack, Wilson, William, Pipicella, Joseph L., Ghaly, Simon, Begun, Jakob, Lawrance, Ian C., Gearry, Richard, Andrews, Jane M. and Connor, Susan J. (2025). Epidemiology and Treatment Patterns of Fistulizing Crohn's Disease in a Large, Real-World Australasian Cohort. Gastro Hep Advances, 4 (4) 100594, 100594. doi: 10.1016/j.gastha.2024.100594 |
|
2025 Conference Publication Handheld ultrasound devices are an accurate alternative to cart-based ultrasound for IBD disease activity assessmentFernandes, R., Swe, E., Khaing, M. M., Gilmore, R., Khoo, E., An, Y. K. and Begun, J. (2025). Handheld ultrasound devices are an accurate alternative to cart-based ultrasound for IBD disease activity assessment. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.1349 |
|
2025 Conference Publication P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptorMoniruzzaman, M., Janjua, T., Begun, J. and Popat, A. (2025). P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptor. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0286 |
|
2024 Journal Article Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort studyGilmore, Robert, Fernandes, Richard, Hartley, Imogen, Arzivian, Arteen, Leong, Rupert, Andrew, Bridgette, Vasudevan, Abhinav, Greeve, Tessa, Moore, Gregory Thomas, Kim, Steven, Lightowler, Daniel, Singh, Abhey, Mahy, Gillian, Mithanthaya, Aditya, Venugopaul, Kannan, Han, Sangwoo, Bryant, Robert, West, Jack, Segal, Jonathan, Christensen, Britt, Corte, Crispin, Ding, Nik, An, Yoon-Kyo and Begun, Jakob (2024). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research. doi: 10.5217/ir.2024.00127 |
|
2024 Journal Article Does improving depression symptoms in young adults with inflammatory bowel disease alter their microbiome?Davies, Julie M., Teh, Jing Jie, Ewais, Tatjana and Begun, Jakob (2024). Does improving depression symptoms in young adults with inflammatory bowel disease alter their microbiome?. Inflammatory Bowel Diseases, 30 (12), 2428-2439. doi: 10.1093/ibd/izae121 |
|
2024 Conference Publication Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated AnemiaBisht, Kavita, An, Yoon-Kyo, Shatunova, Svetlana, Wang, Ran, Barbier, Valerie, Giri, Rabina, Amiss, Anna, Tang, Yifu, Alexander, Kylie, Millard, Susan, Winkler, Ingrid G., Pettit, Allison, Begun, Jakob and Levesque, Jean-Pierre (2024). Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-193349 |
|
2024 Journal Article Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease CoalitionAkyüz, Filiz, An, Yoon Kyo, Begun, Jakob, Aniwan, Satimai, Bui, Huu Hoang, Chan, Webber, Choi, Chang Hwan, Chopdat, Nazeer, Connor, Susan J, Desai, Devendra, Flanagan, Emma, Kobayashi, Taku, Lai, Allen Yu-Hung, Leong, Rupert W, Leow, Alex Hwong-Ruey, Leung, Wai Keung, Limsrivilai, Julajak, Muzellina, Virly Nanda, Peddi, Kiran, Ran, Zhihua, Wei, Shu Chen, Sollano, Jose, Teo, Michelle Mui Hian, Wu, Kaichun, Ye, Byong Duk and Ooi, Choon Jin (2024). Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition. Intestinal Research, 23 (1), 37-55. doi: 10.5217/ir.2024.00089 |
|
2024 Journal Article Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trialPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark G., De Cruz, Peter, Fung, Caroline Lan-San, Redmond, Diane, Chan, Webber, Mourad, Fadi, Kermeen, Melissa and Leong, Rupert W. (2024). Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial. Clinical Gastroenterology and Hepatology, 22 (11), 2299-2308. doi: 10.1016/j.cgh.2024.04.019 |
|
2024 Journal Article Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trialChoy, Matthew C., Li Wai Suen, Christopher F. D., Con, Danny, Boyd, Kristy, Pena, Raquel, Burrell, Kathryn, Rosella, Ourania, Proud, David, Brouwer, Richard, Gorelik, Alexandra, Liew, Danny, Connell, William R., Wright, Emily K., Taylor, Kirstin M., Pudipeddi, Aviv, Sawers, Michelle, Christensen, Britt, Ng, Watson, Begun, Jakob, Radford-Smith, Graham, Garg, Mayur, Martin, Neal, van Langenberg, Daniel R., Ding, Nik S., Beswick, Lauren, Leong, Rupert W., Sparrow, Miles P. and De Cruz, Peter (2024). Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. The Lancet Gastroenterology & Hepatology, 9 (11), 981-996. doi: 10.1016/s2468-1253(24)00200-0 |
|
2024 Journal Article Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: a systematic review and future perspectiveParigi, Tommaso Lorenzo, Solitano, Virginia, Armuzzi, Alessandro, Acosta, Manuel Barreiro de, Begun, Jake, Ben-Horin, Shomron, Biedermann, Luc, Colombel, Jean-Frederic, Dignass, Axel, Fumery, Mathurin, Ghosh, Subrata, Kobayashi, Taku, Louis, Edouard, Magro, Fernando, Panaccione, Remo, Rausch, Astrid, Reinisch, Walter, Selinger, Christian, Jairath, Vipul, Danese, Silvio and Peyrin-Biroulet, Laurent (2024). Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: a systematic review and future perspective. United European Gastroenterology Journal, 12 (9), 1266-1279. doi: 10.1002/ueg2.12671 |
|
2024 Journal Article International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statementLu, Cathy, Rosentreter, Ryan, Parker, Claire E, Remillard, Julie, Wilson, Stephanie R, Baker, Mark E, Bhatnagar, Gauraang, Begun, Jakob, Bruining, David H, Bryant, Robert V, Christensen, Britt, Feagan, Brian G, Fletcher, Joel G, Gordon, Ilyssa, Henderson, Gaylyn, Jairath, Vipul, Knudsen, John, Kucharzik, Torsten, Lesack, Kyle, Maaser, Christian, Maconi, Giovanni, Novak, Kerri, Rimola, Jordi, Taylor, Stuart A, Wilkens, Rune and Rieder, Florian (2024). International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement. The Lancet Gastroenterology & Hepatology, 9 (12), 1101-1110. doi: 10.1016/s2468-1253(24)00265-6 |
|
2024 Conference Publication The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase HistoryAllegretti, Jessica R., Panés, Julián, Peyrin-Biroulet, Laurent, Sands, Bruce E., Yarandi, Shadi, Huang, Kuan-Hsiang G., Germinaro, Matthew, Zhan, Jia, Zhang, Hongyan, Begun, Jakob, Kierkuś, Jarosław, Kravchenko, Tetiana, Hisamatsu, Tadakazu, Rubin, David T., Bressler, Brian and Dignass, Axel (2024). The Efficacy of Maintenance Treatment with Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Maintenance Study Results at Week 44 by Biologic/Janus Kinase History. 2024 ACG Annual Meeting, Philadelphia, PA United States, 25-30 October 2024. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.14309/01.ajg.0001034328.68326.43 |
|
2024 Journal Article Group B Streptococcus vaginal colonisation throughout pregnancy is associated with decreased Lactobacillus crispatus and increased Lactobacillus iners abundance in the vaginal microbial communityMaidment, Toby I., Pelzer, Elise S., Borg, Danielle J., Cheung, Eddie, Begun, Jake, Nitert, Marloes Dekker, Rae, Kym M., Clifton, Vicki L. and Carey, Alison J. (2024). Group B Streptococcus vaginal colonisation throughout pregnancy is associated with decreased Lactobacillus crispatus and increased Lactobacillus iners abundance in the vaginal microbial community. Frontiers in Cellular and Infection Microbiology, 14 1435745, 1-11. doi: 10.3389/fcimb.2024.1435745 |
|
2024 Conference Publication A cross section of inflammatory bowel disease management in older persons in Australasia: Crohn's Colitis Cure (CCC) data insights programSeng, Crystal, Su, Wai Kin, Wilson, William, Haifer, Craig, Williams, Astrid-Jane, Forbes, Angela, Lawrance, Ian, Lynch, Kate, Brett, Laurel, Begun, Jakob, Connor, Susan J., Andrews, Jane and Walker, Gareth (2024). A cross section of inflammatory bowel disease management in older persons in Australasia: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case seriesSwe, Ei Phyu Phyu, Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2024). Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Janus kinase inhibitors for the management of acute severe ulcerative colitis: An Australian multicentre studyGilmore, Robert, Fernandes, Richard, Subhaharan, Deloshaan, Mohsen, Waled, Thin, Lena, Chin, Simone, Con, Danny, De Cruz, Peter, Demase, Kathryn, Sparrow, Miles P., Lucas, Sarah, Garg, Mayur, Bryant, Robert, Segal, Jonathan, Christensen, Britt, Begun, Jakob and An, Yoon-Kyo (2024). Janus kinase inhibitors for the management of acute severe ulcerative colitis: An Australian multicentre study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
